文献速递胃肠外科围术期管理与 ERAS

单孔机器人辅助微创食管切除术的初步临床结局

Initial clinical outcomes of uniportal robotic-assisted minimally invasive esophagectomy.
PubMed 文献 · Surg Endosc · 2026-05-28

结果显示R0切除率95%,中位淋巴结检出34枚,Clavien-Dindo II级及以上并发症发生率29%,无90天死亡,结论认为该术式安全可行。

要点

  • 单孔机器人辅助微创食管切除术R0切除率达95%,中位淋巴结检出34枚。
  • Clavien-Dindo II级及以上并发症发生率29%,无90天死亡。
  • 中位术后住院15.0天,胸管留置5.5天,术后疼痛评分持续较低。

核心结论

  • 单孔机器人辅助微创食管切除术在食管癌患者中安全可行,围术期与短期结局可接受。

研究设计与样本

  • 手术经肋间切口使用da Vinci Xi系统完成,主要结局为R0切除率。

主要发现

  • McKeown术式占52%,Ivor-Lewis术式占48%,R0切除率95%。
  • 中位控制台时间155分钟,中位淋巴结检出34枚,中位出血量450 mL,中转胸腔镜手术率5%。
  • Clavien-Dindo II级及以上并发症发生率29%,无90天死亡。
  • 中位胸管留置时间5.5天,中位术后住院时间15.0天,术后疼痛评分持续较低。

临床怎么用

  • 对于适合微创食管切除的食管癌患者,单孔机器人辅助术式可作为安全可行的选择之一。
  • 该术式可获得较高的R0切除率和淋巴结检出数,围术期并发症与住院时间在可接受范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robotic-assisted minimally invasive esophagectomy has improved perioperative outcomes; increased surgical proficiency has promoted interest in uniportal techniques. We aimed to evaluate the perioperative and short-term outcomes of a novel uniportal robotic-assisted minimally invasive esophagectomy performed through an intercostal incision using the da Vinci Xi system. METHODS: We retrospectively reviewed patients who underwent uniportal robotic-assisted minimally invasive esophagectomy between September 2024 and July 2025. The primary outcome was the complete resection rate with microscopically negative margins (R0). Secondary outcomes included perioperative and short-term outcomes, including operative time, lymph node yield, blood loss, conversion rate, postoperative pain scores, opioid requirements, complication rates, chest tube duration, and hospital stay. RESULTS: Twenty-one patients (median age, 64 years; 86% male) underwent uniportal robotic-assisted minimally invasive esophagectomy. Squamous cell carcinoma was the most common histology (81%); 62% had stage III-IV disease, and 71% received neoadjuvant therapy. The McKeown and Ivor-Lewis procedures were performed in 52% and 48% of cases, respectively; complete resection was achieved in 95%. The median console time, lymph node yield, and blood loss were 155 min, 34, and 450 mL, respectively. One patient (5%) required conversion to thoracoscopic surgery. The postoperative pain scores were consistently low. The median chest tube duration and postoperative hospital stay were 5.5 and 15.0 days, respectively. Clavien-Dindo grade II or higher complications occurred in 29% of the patients, with no 90-day mortality. CONCLUSION: Uniportal robotic-assisted minimally invasive esophagectomy is safe and feasible, with acceptable perioperative and short-term outcomes in patients with esophageal cancer.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Kuo TF, Huang PM, Chen KC, et al. Initial clinical outcomes of uniportal robotic-assisted minimally invasive esophagectomy. Surg Endosc. 2026. PMID: 42209859. doi:10.1007/s00464-026-12826-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。